maheshs7793

Impact of COVID-19 on Diabetes Treatment Market in Pharmaceutical Industry


OVERVIEW

The COVID-19 has posed a complex challenge in front of different healthcare market players, which has badly impacted the worldwide market. The COVID-19 disease caused by the SARS-CoV-2 virus is a newly discovered infectious disease, and it has been reported that along with respiratory organs it also affects the other organs such as kidney, heart, digestive tract, blood and nervous system.
This has been reported that the older people and people having pre-existing medical conditions such as diabetes, asthma among others are more vulnerable to prevailing COVID-19. If people having diabetes develop COVID-19 infection, it becomes harder to treat the fluctuating blood glucose levels and hence it becomes difficult to treat the diabetes complications. As the diabetic patients have weak immune system, those people are generally took longer recovery period. Moreover, the environment of elevated blood glucose levels provides and ambient condition for the survival of coronavirus for a longer period of time.
The prevailing COVID-19 has resulted in lockdown in order to prevent the uninfected people from those of infected one; this lockdown has created a stressful mind among the people having chronic disease such as diabetes related to medicines and diagnostic tools. The COVID-19 is likely to infect people having diabetes with 50% higher risk as compared to those who do not having diabetes. Thus, it is very much important for diabetic patients to maintain accurate blood glucose level and also to strengthen the immune system to stay protected from getting infected from the virus.
FIGURE: 1 TOP MOST DIABETES PREVAILING COUNTRIES (2019)
the prevalence of diabetes is increasing worldwide it has become important to provide patients with proper medicines and accurate diagnostic tools during the prevailing pandemic of COVID-19, this is the reason why pharmaceutical companies and government are taking several steps in order to deal with cumbersome condition.

PRICE IMPACT:

As no such treatment has been discovered yet for coronavirus, the fear of getting infection led the people to remain safe at their home, as a result of which various businesses around the world is suffering a lot involving pharmaceutical companies among others.
As India relies on China for 70% of drug intermediates and bulk drugs, COVID-19 is expected to hike the price of the medicines used for diabetes treatment.
For instance,
· India relies on China for Metformin Hydrochloride which is used to control the high blood sugar level in patients having type II-diabetes. According to a report it has been suggested that the stock of Metformin Hydrochloride lasted for March 2020, and now India is facing scarce of this ingredient, this is likely to hike the price of diabetes treatment medicines.
· As per the new report published by CBS news stated that Medtronic, headquarter in Dublin, Ireland is a medical technology company, the company depends on import of some raw materials from others regions of world for manufacturing of insulin pumps and others products, but as a result of lockdown and ban across the borders, the company is likely to suffer from shortage of raw material that will pose a direct impact on manufacturing and hence led to price increase of insulin pumps.
· This has been reported that makers of electronic drug delivery systems in India rely on China for several electronic components. Almost all electronic makers are increasing prices by 3-5% due to shortage of imports and export activities which ultimately led to shortage of parts. As electronic components are used for the manufacturing of insulin pumps the increasing prices of electronic component led to hike in price of insulin pumps.
This thus signifies that due to COVID-19 pandemic the price of insulin pumps and the medicines used for diabetes treatment will increase across the globe.

IMPACT OF COVID-19 ON DEMAND

The coronavirus has affected the various regions of the world and caused widespread closure of market players and local manufacturing plants. This lockdown and isolation has adversely impacted the global economic activity.
COVID-19 is expected to be an opportunity for diabetes treatment market, as the patients having diabetes are at the higher risk of getting COVID-19 infection.
THE IMPACT OF COVID-19 INFECTION ON DIABETIC PATIENTS
Diabetic patients have impaired immune systems and are prone to infectious agents as they have lost the ability to fight against pathogenic organisms.
Moreover diabetic patients have poor glycemic control which also led to increasing chances of viral infection.
Most of the diabetic patients are founded to be obese and obese people are also at a higher risk of COVID-19 infection due to less metabolism activity which even led to the weak immune system.
Diabetes is treated with angiotensin converting enzymes inhibitors and this has been discovered that coronavirus binds to the target cells through this enzyme, an enzyme expressed in the blood vessels and lungs. As an increasing level of ACE2 enzyme founded in diabetic patients, the chances of COVID-19 also increases in such patients.
As the diabetic patients are more prone to COVID-19 infection, they usually look for proper glycemic control. In order to control diabetes, a diabetic patient usually relies on advanced medicines and insulin pumps.
Along with this the market players engaged in the manufacturing of diabetes management tools that are continually making profit even, during the prevalence of COVID-19.
For instance,
· In a post of May 2020, Tandem Diabetes Care, Inc, the San Diego- based company maker of electronic insulin pumps among other diabetes management devices commented that the company is still making profit due to positive customer feedback on its products such as slim X2 with Control-IQ technology (electronic insulin pump).
This suggests that increasing prevalence of COVID-19 poses a life threating challenges to diabetic patients and hence enhances the demand of diabetes treatment solution. This thus signifies that COVID- 19 is accelerating the demand of diabetes treatment market.

IMPACT ON SUPPLY

Due to pertinacious COVID-19 lockdown, sanctions have been imposed by the governments of various countries. These restrictions and barriers across countries borders led to a decrease in supply of APIs (active pharmaceutical ingredients) needed for drug manufacturing and raw materials required for manufacturing of devices including insulin pumps.
China is considered to be the manufacturing hub of most of the electronic raw materials and India among other countries is heavily dependent on China for electronic raw materials needed for manufacturing of insulin pumps.
Moreover, India procures 70% of APIs (active pharmaceutical ingredients) included Metformin, a diabetes treatment medicine from China, but due to continuous barrier the country is unable to achieve delivery of such products at correct time and in proper amount.
As per the report published on March, 2020 stated that India is suffering from shortage of insulin and other refrigerated medicines due to COVID-19 impact. In India most of the diabetic patients relies on three to four million of insulin shots in each month and these insulin have to keep in cold temperature zones. While the COVID-19 lockdown a shortage of refrigerated vans have been reported that posed a problem for supply of refrigerated insulin to many parts of India.
This signifies that due to continuous lockdown and several restrictions by government authorities the market players and patients are facing disruption of supply chain for raw materials.

STRATEGIC DECISIONS of MANUFACTURERS

Collaboration, agreements, strategic initiatives by market players such as Medtronic, Novo Nordisk India Pvt Ltd, among others in the diabetes treatment market and will help them to expand their product portfolio and to provide with appropriate solutions to physicians and patients. This in turn will lead to increasing product sales and hence will put a positive impact on overall company’s revenue.
Diabetes drug and device manufacturing companies are taking so many strategic decisions in order to cope up with the current scenario of COVID-19. The market players engaged in the manufacturing of diabetes treatment are collaborating so as to accelerate the development of medicines and devices.
The market players have already taken several kinds of strategic initiatives in order to cope up with the corona virus situation.
For instance,
· In July 2020, Tandem Diabetes Care, Inc. signed a collaborative agreement with one of the med- tech company, Medtronic. The agreement signed by these two companies reflects patent cross-license agreement for t: slimX2 insulin pump manufactured by Tandem Diabetes Care, Inc. and MiniMed 670G insulin pump manufactured by Medtronic.
· In June 2020, Medtronic received an award of USD 337 million for enhancing the research and development for diabetes treatment products. This award has helped the company to boost up in research activities so as to develop an innovative insulin management solution amid the novel COVID-19 prevalence.
· In April 2020, Medtronic, a company engaged in manufacturing of insulin pumps done a rapid expansion of its distribution and production facilities in order to provide the proper diabetic solutions across the world. Moreover, the company’s employees are working every day in order to fulfill the company’s mission to restore health and alleviate life.
· In March 2020, Tandem Diabetes Care, Inc. posted that as restriction were imposed by the California’s governor at the company’s headquarter in San Diego, most of the team workers are working remotely so that the company can maintain the supply chain of their product to their customers worldwide.
With the increasing demand and increasing sales of diabetes treatment medicines and devices, are fueling the growth of diabetes treatment market.
Thus, the market players operating in the diabetes treatment market are adopting several strategies, including collaboration, agreements, market expansion to enhance their business. These strategic decisions by the market players are expected to provide significant opportunities for the market players operating in the diabetes treatment market.

CONCLUSION

As the pandemic of COVID-19 has resulted in several restrictions throughout the borders but still manufacturers of diabetes medicines and devices are able to manage their stocks. Various manufacturers have allowed their manufacturers to work remotely for manufacturing of insulin pumps and medicines at various manufacturing facilities across safe regions of world helping them to maintain continuous supply chain. Moreover, by raising price of diabetes treatment the market players are gaining extra profit which is helping them to combat the negative effect on overall revenue.
Comment
Suggested
Recent
Cards you may also be interested in
Fioricet Medication - Should Know About
Fioricet is a pain killer and it consists of acetaminophen, caffeine, and Butalbital. These components contribute to relaxing muscles, improving blood pressure, and relieving pain and high body temperature. This drug usually helps people calm moderate to severe medical conditions like tension headaches, fever, muscle contractions, etc. Uses of Fioricet Take Fioricet only by the advice of a physician. Make sure you have a prescription that is required to buy Fioricet 40mg online overnight or offline. Always follow the directions on the label and make it a habit while consuming any kind of medicinal formula. Take a note of your dosage as prescribed by your doctor. The overdose side effects might occur due to carelessness in the consumption of Fioricet. Keep your doctor posted about the changes in your body related to the reaction towards the medication. Do not share your medicine with anyone, especially someone with a drug abuse history. This medication isn’t supposed to be taken without the advice and the prescription of a doctor. Though you can buy Fioricet online. Keep it in a safe place and make sure to keep a track of the contents. Selling or giving out Fioricet without a prescription is illegal in many parts of the world. In case the drug upsets your stomach, ingest it with light food. Store it in a dry, well-lit area at room temperature. In case of a missed dose, do not consume double doses to make it up for a missed dose.   Precautions for Consumption Since this medication can make you feel drowsy, you can avoid doing things that require alertness. Try resting for a couple of hours and then doing whatever you feel like. Avoid alcohol as it can magnify the effects of the medication and it can also severely harm your liver. Certain medical combinations can react together and cause harm to the patient’s body so it is advisable to monitor if you are taking any other medication for cold or pain etc.  Inform your doctor and educate yourself on it. Avoid taking medications with APAP in them. Avoid caffeine pills, or ADHD-related medications, etc. while consuming Fioricet. Exercise caution if you suffer from hepatitis, porphyria, cardiovascular diseases, or anaemia. Though very rare, there are chances of severe skin allergies in patients due to Acetaminophen. Make sure your doctors are always updated with your medical condition and your response to certain medications. This way it will be easier to predict any upcoming progress in your condition. If there is a special risk patient like a senior citizen or a pregnant woman, caution should be taken if Fioricet is prescribed to them. Because the effects can be different in senior citizens and can be transferred to the unborn child in the case of pregnant women. Breastfeeding women also need to take care of this as the contents of the medication can be transferred to the child. Side Effects Even though Fioricet is quite a safe medication and has proven to be life-changing many times in medical history. But being a medication, it is bound to have some chemical side effects. A doctor always prescribes a medication keeping at par the risks of side effects.  Some of the side effects of Fioricet are- swelling in body parts, hives, unusual colored urine, rashes, vomiting, palpitations, drowsiness, nausea, etc. in case, there is any serious condition, you should immediately contact a doctor. Contact your doctor right away if, you observe any of the symptoms for instance- mood swings, palpitations, seizures, etc. even though serious allergic reactions are rare with the consumption of Fioricet, but in any case, if you observe rashes, swollen body parts, drowsiness, itching, etc. after the ingestion of the medication rush for medical help do not try to treat such situations on your own. Every drug has different reactions in different bodies, so if you feel uncanny and uncomfortable, see a doctor. Conclusion Patients can easily buy Fioricet online overnight fast shipping in USA,and make the best use of it, only when properly monitored and handled. Fioricet has changed lives, but only when properly utilized. So, make sure you know well about the medication before consuming it and make sure your health is in safe hands with Fioricet. ORIGINAL SOURCE: What All Should One Know About- Fioricet
RIMS Trauma Hospital
Every day people enter the gates of Rims Trauma Hospital to find themselves or their loved ones. With an unwavering commitment to best practice that meets international standards, regulations and quality systems, we ensure that patient needs are met satisfactorily under one roof. Rims Trauma Hospital is located in the heart of the bustling city of Karachi on Shahrah-e-Faisal Road, near Nursery Bridge. Thanks to this unique location it has easy access to all the city quadrants. RIMS Trauma conceived as the start of an arts hospital with the vision of providing low-cost health care at an affordable cost to all economic classes. Over the years, the hospital has become the largest hospital in the country with over 100 beds. And we have the largest number of beds and ventilators in town. the hospital excels in all aspects of medicine, surgery, diagnosis and medical support services. RIMS Trauma has more than 15 items. Considering patient care as a priority, we provide 24-hour emergency services, intensive care, outpatients, outpatients and childcare facilities not only in the city but also in patients from remote parts of Sindh, Balochistan, Khyber Pakhtunkhwa and Punjab. RIMS Trauma pioneered in many special areas. We have also developed other facilities such as the Physiotherapy Development Unit, Dental Care and implantation procedures. These courses are led by specialized and highly trained doctors. Rims Trauma Hospital is renowned for its many surgical and surgical procedures. We have a close relationship with the College of Physicians and Surgeons of Pakistan. We also enjoy the privilege of being the cheapest hospital in the city. We are proud to serve with the greatest compassion, compassion and care in the event of emergencies, accidents or disasters in the city. We believe that anyone and everyone who needs health care is our problem. The doors of Rims Trauma Hospital are always welcome for those in need. Inexpensive consultation with treatment and the latest in-country and national patient services. Address PECHS Block 6, Sharah-e-faisal, Near Nusery Bridge, Karachi, Pakistan PTCL: 021-34311340-3 Email: info@rimstrauma.com
Significant Impact of COVID-19 on PPE Kits in Healthcare Industry
COVID-19 Impact on PPE Kits in Healthcare Industry Personal protective equipment is commonly referred to as "PPE." PPE is a worn equipment which helps to minimize exposure to hazards from the workplace illnesses and injuries. These injuries may result from contact with radiological, physical, chemical, mechanical, electrical, mechanical, or other workplace hazards. PPE includes the items such as safety glasses, gloves and shoes, earplugs or muffs, respirators, or coveralls, hard hats, and full body cover suits. Choosing the right PPE helps to reduce the exposure to hazards and is essential to laboratory safety. SHORTAGE OF PERSONAL PROTECTIVE EQUIPMENT ENDANGERING HEALTH WORKERS WORLDWIDE The World Health Organization has warned that extreme and mounting disruption to the worldwide delivery of personal protective equipment (PPE) – resulting from growing demand, panic buying, hoarding, and misuse – is placing lives at chance from the brand new coronavirus and different infectious diseases. Healthcare employees rely upon private shielding systems to shield themselves from being infected. However, shortages are leaving doctors, nurses, and different frontline employees dangerously ill-prepared to take care of COVID-19 sufferers,. Industry and governments have to act speedily to reinforce delivery, ease export regulations, and positioned measures in vicinity to prevent hypothesis and hoarding. “We can’t prevent COVID-19 without defensive medical examiners first” stated WHO Director-General Dr Tedros Adhanom Ghebreyesus. IMPACT OF COVID-19 ON PERSONAL PROTECTIVE EQUIPMENT The current coronavirus disease outbreak (COVID-19) has spread worldwide. All COVID-19-affected countries throughout the world are taking containment measures and doing their utmost to combat the disease in order to prevent it from spreading further and to limit death. In the early discovery of cases, contact tracing, and treatment of patients, the public health workforce and healthcare workers in clinical settings play a critical role. In order to combat any infectious disease in a crisis, healthcare practitioners and public health workers must have access to personal protective equipment (PPE) and utilize it consistently and correctly. As the COVID-19 pandemic spreads across the globe, the demand for personal protective equipment has skyrocketed. Many nations, including India, have experienced a temporary scarcity of PPE due to the pandemic's rapid spread. The absence of personal protective equipment (PPE) has harmed the morale of healthcare workers (HCWs) and other frontline troops fighting the coronavirus epidemic, which has afflicted over 22,000 health workers in 56 nations. Some have succumbed to it in countries all over the world, including India (WHO).. Moreover, an increase in the potentially infectious patients seeking testing and care accelerates the COVID-19 pandemic all over the world. Spread of COVID infection all over the world is generating the demand for PPE kits such has like face masks, gloves, goggles, air-purifying respirators, respirators face shields, and gowns among health care employees. As a result of shortage in all kinds of PPE, developed high demand across the globe. For instance · United Nations Children's Fund plays an important role in the delivery of PPE. The fund shipped more than 653.4 million items of PPE in 140 countries. CONCLUSION The spread of the novel coronavirus has triggered significant market damage across the world. Most businesses have stopped immediately, and the effect of the pandemic has been on all industries. The towns were closed down, and social distancing has become a modern norm. Government along with the private sector can play a vital role in reviving the sector. The government is providing financing assistance for needs arising from COVID-19; the private sector can take care of large investments and expertise required in developing countries. Apart from this, strong engagement with governments and local stakeholders will continue to contribute significantly to the development of the sector. In the starting days of pandemic, drastically boots the demand of personal protective equipment all over the globe. The use of personal protective equipment “specially medical masks” has become more popular in the world and also other PPE such has gloves, face shields, gowns, googles and other items have experienced rise in the demand among essential workers and frontline health care employees. Companies are making the strategic action to increase the supply to meet the demand of personal protective equipment in the market. Government has also introduced many polices and initiatives which would help manufactures to maintain in stable growth in current dynamic situation.
How COVID-19 Impacted on Bevacizumab in Healthcare Industry ?
COVID-19 Impact on Bevacizumab in Healthcare Industry In the city of Wuhan, China the Coronavirus disease (COVID-19) outbreak is originated. Coronavirus disease (COVID-19) has spread across the globe, with large number of cases having been reported worldwide. The Coronavirus disease (COVID-19) pandemic is not only creating health crisis but also it is unfavorably affecting on healthcare, economies and pharmaceutical sector as well as at their core. As COVID-19 is the infectious disease, its spread is endless. It have causes a nationwide outbreak as well as public health crisis. Cancer treatment and therapies drugs manufacturing companies have also faced some difficulties in manufacturing and distribution of the drugs and medication due to locked down, supply chain and social distancing restrictions. In some recent studies, it was stated that Bevacizumab, an anti-VEGF drug, approved by the FDA and widely used in clinical oncotherapy, is a promising drug for ALI/ARDS in COVID-19 through suppression of pulmonary edema which have increased its demand in the market and also increasing cancer patients have also driven the market demand and supply. PRICE IMPACT The Coronavirus disease (COVID-19) pandemic has an enormous impact on the global economy market. The demand for cancer treatment products has increased along with its prices in the treatment of COVID. In addition, the sum of research and development and marketing, selling, and administrative expenses have been increased in 2020, which is driven primarily by the development expenses for COVID-19 therapies. For instance, Bevacizumab plus standard care markedly improves the oxygen ratios in COVID 19 patients and shows improvement in oxygen-support status, patients were discharged, and none of the patients have shown worsen oxygen-support status nor die. Also, the demand for cancer treatment products will be increased, and the products are upgraded by top importer countries like U.S., which have increased the sales and prices of the bevacizumab. For instance, The drug Avast in (bevacizumab) has been increased to $842 for a supply of 4 milliliters dose in 2020. Due to the increase in demand, the use of bevacizumab in the COVID treatment and increase in production and manufacturing expenses have contributed to product prices. IMPACT ON SUPPLY CHAIN The COVID-19 pandemic has transformed many organizations’ business environment; several problems, including export and travel ban by some producing countries and lockdowns that have caused producers to (temporarily) shut down, have disrupted supply access. Difficulties or delays in manufacturing, sales, or marketing; supply disruptions, shortages, or stock-outs at our facilities; and legal or regulatory actions all are caused due to the COVID 19 pandemic. But it does not affect the sales and supply of the drug bevacizumab that much because of the rise in new diagnoses or cancer and the efficiency of the drug in treating the COVID patients. These are some of the reasons which have maintained the supply of the drug throughout the year With the rise in demand and supply of the drugs, many manufacturing companies have launched their new products, which have increased their sales. For instance- · The sales of the drug MVASI (bevacizumab) from the manufacturing company Amgen Inc. have increased more than 20% in the U.S., which is USD 121 million in 2019 to USD 650 million in 2020 and for the rest of the world, drug sales increased from USD 6 million in 2019 to USD 142 million in 2020. This increase in the supply of the drug is with the increasing treatment for cancer. · Similarly, the sales of the global segment generics, which include biologics drugs such as bevacizumab of the company Dr. Reddy’s Laboratories Ltd, have also been increased from USD 1,858.27 million in 2019 to USD 2,079.96 million in 2020. This increase in sales is due to the increase in healthcare and Research & Development due to COVID 19. IMPACT ON DEMAND Coronavirus disease (COVID-19) is an infectious disease caused by a SARS-CoV-2 virus, while a large population is affected by this COVID-19 virus. Coronavirus disease 2019 (Covid-19) is an ongoing worldwide pandemic; nearly all the countries have taken initiative action under locked down and social distancing restriction. Reduction in cancer treatment across the globe has affected the demand for cancer treatment and their drugs like bevacizumab, especially in the first quarter, but after the second quarter of 2020, the demand for the drug has increased because of its Efficacy and tolerability of in patients with severe COVID-19. For Instance- Recent evidence revealed higher blood Vascular Endothelial Growth Factor (VEGF) levels in COVID-19 patients compared with healthy controls. VEGF is considered the most potent vascular permeability inducer. Numerous studies have revealed that VEGF was a key factor and a potential therapeutic target in ALI and ARDS. Bevacizumab, an anti-VEGF drug, approved by the FDA on February 26, 2004, and widely used in clinical oncotherapy, is a promising drug for ALI/ARDS in COVID-19 through suppression of pulmonary edema. Also, the increase in cancer patients and the rise in the demand for the treatment of various types of drugs have propelled the market demand and sales of major market players. For instance, · There is an increase in the sales of biosimilar drugs which includes bevacizumab, for major market players. For instance, the manufacturing company Pfizer Inc., the sales of biosimilar segment is increased from USD 1,527 million to USD 911 million with the increase in demand for the drugs in COVID patients and the cancer treatment. STRATEGIC DECISIONS FOR MANUFACTURERS A large population is affected by this COVID-19 virus, and its spread is expanding worldwide for the last few months. To deal with the COVID-19 outbreak challenges, many bevacizumab and biosimilar market players are creating new strategies. The company is now opting for digital media such as telecommunication, mobile applications, webinars, and other digital media to support patient requirements to tackle the pandemic situation and increase the company sales with the increasing demand and growth. Moreover, to accomplish the market demand, small market players are utilizing the partnership agreement strategy. It is predicted that these strategies are anticipated to escalate up the company revenue and its growth in the forecasted period. They have launched new products and formed strategic alliances with each other to carry on the supply during the pandemic. For instance- · In 2020, Amgen Inc. had advanced their innovative pipeline, successfully integrated MVASI, acquired in November 2019, a biosimilar to Avast in (bevacizumab), and has advanced their international expansion continued to provide an uninterrupted supply of their medicines globally through the COVID-19 pandemic · In May 2020, the Food and Drug Administration approved atezolizumab in combination with bevacizumab (TECENTRIQ and AVASTIN, Genentech Inc.) for patients with unrespectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy CONCLUSION It can be concluded that the COVID-19 pandemic has a positive impact on the global bevacizumab market with the increase in the price, supply, and demand of the bevacizumab. However, in the crisis call, pharmaceutical market players, government bodies, and healthcare organizations work closely with healthcare professionals, customers, and patients for the betterment of public health and to fulfill the demand. However, companies and government bodies exclusively concentrate on how they can make the most effective and best contribution to control the spread of the virus and save lives. They are also ramping up the production of essential medication to a new level and ensure that speed doesn’t affect or destroy the quality of products.
What Impacted COVID-19 on Niemann-Pick Disease ?
Impact of COVID-19 on Niemann-Pick Disease in Healthcare Industry OVERVIEW A novel coronavirus, SARS-CoV-2, appeared in December 2019 in Wuhan, China, spreading much faster than its predecessors and has already infected millions of patients worldwide as of April 19, 2020. As the scope of the current COVID-19 outbreak has reached the proportion of pandemics, significant international efforts in public health are underway to control the epidemic. The covid-19 pandemic majorly impacted the rare diseases patients because, during the pandemic, the need to provide high-level care for a large number of patients with COVID-19 has affected resourcing and limited the routine maintenance of all other conditions. The impact of health emergencies particularly faced by the rare disease communities, organizations, clinics, and other healthcare providers. The health economic challenges faced by patients and their families, institutions, research organizations, and healthcare providers during the pandemic outbreak have demonstrated the importance of ensuring continuity of care in the management of rare diseases, including adequate diagnostics and monitoring protocols, and highlighted the need for a structured emergency strategy. Niemann-Pick disease is a rare, inherited disease that affects majorly body's ability to metabolize fats such as cholesterol and lipids within the cells. Over time, these cells got malfunctioned and died. The disease can affects the brain, spleen, nerves and, if get severe, may affect lungs, bone marrow, and other organs. The disease can occur at any age but majorly affects children. There is no known cure for the disease, and sometimes it may be fatal for children, the only treatment is focused on helping people live with their symptoms. STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS As such, market participants are involved in the production of drugs, expanding their business through a variety of programs, including collaboration, contracts, and pipeline development, collaboration, and market expansion. It is expected that the strategic decisions of these companies will provide significant opportunities for market participants operating in the Niemann-Pick Disease market. For instance, · In July 2020, Abbott announced that it had received FDA approval for the use of the Patient Controller App on compatible personal Apple smartphone devices. The approval will allow the patient living with neurological conditions to manage their therapy directly from personal smartphone. · In May 2020, Philips, a global leader in health technology, joined forces with the American Telemedicine Association (ATA) to help further the adoption of telehealth across the industry, demonstrating its commitment to connecting care across acute, post-acute, and home care settings. The continued collaboration spotlights telehealth's growing adoption and momentum amidst COVID-19 and the need to convey the exponential shift to telehealth capabilities. · In U.S., NIH supports the research survey of “CURE EPILEPSY ORGANIZATION” to examine the impact of Covid-19 on Rare Disease Community. The survey includes more than 200 rare diseases including the brain, immune system disorders, heart, lungs, brain development diseases, and more. IMPACT ON DEMAND The Coronavirus zone is the result of various markets around the world. This is the cause of the widespread closures and isolation that are affecting world economic activity. As the cases increases in the month of April 2020, the sudden surge in demand has seen, and drugs and medical devices went out of stock. Moreover, the decrease in the revenue of the key market players depicted in their quarterly results, such as Medtronic, among others, gave the evidence of decline in the demand for medical devices due to the emergence of the COVID-19 pandemic. For instance, · Medtronic reported a decline of 1% in its brain therapies net sales of the financial results of 2020 as compared to 2019. The reduction was primarily motivated by the detrimental effects of the COVID-19 pandemic and the subsequent deferral to companies of medical procedures. · Impact on rare disease organization also faced significant fundraising income loss, this consequential income loss may leads to loss of various people jobs associated with the organizations. The cutting or income loss leads to the reducing staff, canceling offices leases, and delay or cutting office programs. The impact of covid-19 majorly impacted the organizations if the revenues loss projections do not change, this will leads to temporarily or permanently shut down of small and middle foundations and organizations. IMPACT ON SUPPLY As the epidemic intensifies, supply chains can be at significant risk due to over-located locations that can potentially be disrupted. The supply chain of drugs, devices, and services has been disrupted. The spread of COVID-19 makes it difficult for governments to use these drugs; the availability of these systems faces constant challenges due to their components of use and limited initial needs. Moreover, as there is no cure for the disease, only physical activities/therapies may suppress the symptoms also affected by pandemics. According to the NORD (National Organization for Rare Disorders), in the U.S. stated that 74% of the population have had canceled medical appointments due to Covid-19 pandemic, 69% of population concerned about their medication and medical supplies. For instance, • In June, ResMed stated that, due to the Covid-19 pandemic company sleep apnea business segment adversely affected including sleep clinics, physician practices, HME suppliers. As new patients are prescribed sleep apnea devices such as PAP, CPAP devices for the treatment through hospitals that are directing their resources to critical care, including COVID-19 treatment. The covid 19 impacts may continue to decrease demand for the sleep apnea devices sale IMPACT ON PRICE Various market players are facing a large number of challenges due to the coming of the novel coronavirus and different strains; one such issue is the uncertainty surrounding the impact of covid-19 on off label drugs demands. Due to the increased coronavirus cases and continuous lockdown, the costs of the drugs and their APIs increase automatically. On the one side, it will increase the revenue of the companies, but a patient may resist buying the products, which ultimately increases the stress level on the patients. Moreover, Due to the pandemic, there is the delay associated with various types of limitations faced by the manufacturers to fulfill the end product order, which has resulted in the less availability of medical devices in the market and due to which the cost of available devices has increased with the several factors. Also, due to the Coronavirus disease (COVID-19) pandemic outbreak, manufacturers are forced to find new contract manufacturers and suppliers for more manufacturing activities to different or unique facilities location that are less impacted by the outbreak. The impact of Covid-19 has created huge price impact on the government as well as on patient families that they have to buy the drugs on higher rate as compared to the average rate. CONCLUSION As this pandemic situation has resulted in many restrictions in different places around the world, still the market players of dealing in rare diseases therapy and services were able to manage their service stock. Different companies dealing in metabolic diseases therapy services were finding out their own way to deal with this pandemic situation. The government and companies around the globe are working together and have issued advice for those undergoing therapies centers during these unprecedented times during COVID 19 lockdown around the world. The supply chain was destroyed, but several steps were taken by the government and companies, which will help them, get their needed output for therapy service. By increasing the material price, the companies can maintain their overall revenue. Thus, different foundations, organizations,, and services center markets are finding ways to deal with this pandemic situation. Read more….
What Impacted COVID-19 on Neurorehabilitation Devices ?
Impact of COVID-19 on Neurorehabilitation Devices in Healthcare Industry OVERVIEW AFTERMATH OF COVID-19 AND GOVERNMENT ROLE The first case of the COVID-19 pandemic was found in Wuhan, China. This pandemic has influenced the whole planet with its major impacts on the economy and businesses across the globe. The COVID-19 spread worldwide in unprecedented ways due to its high infectious and contagious nature. Various countries announced the complete lockdown just after the declaration of COVID-19 as a pandemic, such as the U.S., India, Germany, and China, to protect them from the spread of the disease. The government imposed lockdown rules, and it had significantly impacted the market. The virus has spread across all regions ranging from North America, Europe, Asia-Pacific, Middle East, and Africa up to South America. The COVID-19 has been declared as a pandemic by WHO due to its increased spread across the globe. The neurorehabilitation process makes a possible reduction in impairments and disabilities and eventually improves the life of the patient. Examples of neurorehabilitation devices are invasive stimulators, non-invasive stimulators, brain-computer interfaces, and neurorobotics, among others. Current rehabilitation is supported by advanced methods based on biofeedback, transcranial brain stimulation system, and BCI system. The prevalence of neurological diseases, rise in technological advancement, the emergence of robotic rehabilitation, and the effectiveness of gaming systems in neurorehabilitation are factors that are propelling the demand of the global neurorehabilitation devices market. However, the shortage of skilled personnel, the high cost of treatment, stringent government regulation may hamper the global neurorehabilitation devices market. IMPACT ON DEMAND Coronavirus disease (COVID-19) is an infectious disease caused by a SARS-CoV-2 virus, while a large pool of the population is affected by this COVID-19 virus. Coronavirus disease (COVID-19) causes acute respiratory illness ranges from mild to severe pneumonia with respiratory failure. In order to minimize the spread of COVID-19, nearly all the countries have taken action, such as the implementation of lockdown and social distancing restrictions. Neurorehabilitation is an important part of the recovery process that has undergone some brain injury. In the COVID-19 pandemic, various charities have worked effortlessly to provide treatment and support to patients suffering from brain injury. During the pandemic, the demand for neurorehabilitation devices was high, but companies were not able to supply the devices to end-users as various restrictions were imposed by the government, such as a travel ban, closed borders, among others. Due to affirmative restrictions, sudden shrink took place in various surgeries. Moreover, the decrease in the revenue of the key market players depicted in their quarterly results, such as Medtronic, among others, gave evidence of the decline in the demand for the medical device due to the emergence of the COVID-19 pandemic. For instance, · Medtronic reported a decline of 1% in its brain therapies net sales of the financial results of 2020 as compared to 2019. The reduction was largely motivated by the detrimental effects of the COVID-19 pandemic and the subsequent deferral to companies of medical procedures The decline in revenue of brain therapy suggests the detrimental effect of COVID 19 on the neurorehabilitation devices market and hence impacted the demand-supply concept. IMPACT ON PRICE Neurological rehabilitation is a program designed for the treatment of people suffering from a disorder or any injury in the nervous system. The devices include non-invasive brain stimulators, robotic neuro systems, brain-computer interfaces, and wearable devices, among others. Due to the pandemic, there is the delay associated with various types of limitations faced by the manufacturers to fulfill the end product order, which has resulted in the less availability of neurorehabilitation devices in the market and due to which the cost of available devices has increased with the several factors. Also, due to the coronavirus disease (COVID-19) pandemic outbreak, manufacturers are forced to find new contract manufacturers and suppliers for more manufacturing activities to different or new facilities locations that are less impacted by the outbreak. IMPACT ON SUPPLY CHAIN The consequences of COVID 19 cannot be underestimated. The product and service providers of neurorehabilitation have made efforts by providing services virtually to meet the demands as people were not frequently visiting the hospitals or clinics for the treatment. To manage such a critical situation, many organizations are looking forward to improving and diversifying the supply chain model in all aspects. Diversified supply chain model anticipated minimizing the export of medical devices as well as increase end-to-end visibility The COVID-19 pandemic has transformed many organizations’ business environments; supply availability has been hampered by a number of issues, including export and travel restrictions by some manufacturing countries and lockdowns that have forced suppliers to (temporarily) shut down. In various countries, neurorehabilitation units have reduced their number of beds, in-patients and out-patient neurorehabilitation centers are restricted to a particular area in order to tackle the pandemic situation STRATEGIC DECISIONS BY MANUFACTURERS As the reality of COVID-19 dawned upon the world, the manufactures and production units of the companies in the global neurorehabilitation devices market swiftly planned for strategies to cope with the effect of the crisis. Major players in the market took various initiatives to cope up with the situation. For instance, · In July 2020, Abbott announced that it had received FDA approval for the use of the Patient Controller App on compatible personal Apple smartphone devices. The approval will allow the patient living with neurological conditions to manage their therapy directly from the personal smartphone · In 2019, Mount Sinai Health System announced an innovative tele-neurorehabilitation program for stroke patients. This therapy can be taken by patients while at their homes with virtual backing from clinicians · In 2020, Esko Bionics Holdings, Inc. announced that it had received FDA 501(k) go-ahead to promote its EksoNRTM robotic exoskeleton for patients with acquired brain injury. It is cleared by FDA for spinal cord injury, stroke, or acquired brain injury rehabilitation These strategies helped the company in coping with the pandemic and ensure business operations, minimize the impact of COVID-19, and providing full support to the government in their efforts to combat the disease and help the front-line workers. CONCLUSION It can be concluded that the COVID-19 pandemic situation has an adverse impact on the market, affecting the price, supply, and demand of neurorehabilitation devices. However, in the crisis call, market players, government bodies, and healthcare organizations are work closely with healthcare professionals, customers, and patients for the betterment of public health. The increasing need of neurorehabilitation devices with increasing number of neurological diseases is expected to drive the market in coming years. The market is expected to decline due to increased restrictions imposed by various governments leading to the closing of non-emergent healthcare facilities, including procedures such as neurorehabilitation procedures.
High Healthcare Expenditure To Drive The Growth Of The Operating Room Management Market
The pandemic has led to a temporary ban on elective surgeries across the globe, which resulted in cancellations of elective surgeries worldwide. According to a report published by researchers of CovidSurg Collaborative, around 28 million surgeries were canceled across the globe during 12 weeks of peak disruption during the COVID-19 pandemic.   To handle the increased surgical volumes, hospitals are increasing OR hours and focusing on better utilization of OR. The COVID-19 will positively impact the ORM software market. It will increase the adoption rate of ORM software as most hospitals will now focus on increasing capacity by using technology to improve efficiency.  The overall cost of healthcare delivery has grown significantly over the last few decades, mainly due to increasing health insurance premiums, the rising demand for quality healthcare services, the rising geriatric population, and the increasing incidence of chronic disorders.  Another important factor attributing to rising healthcare costs is the high dependency on traditional and outdated methods such as paper-based patient records, which leads to an increase in readmission rates, medical errors, and administration costs.  Different governments and healthcare systems worldwide are now focusing on controlling rising healthcare costs by minimizing patient readmissions, medical errors, and administration costs with the effective utilization of various healthcare IT solutions. Operating rooms or ORs account for 40% of the total hospital expenses and constitute ~70% of the total revenue generated.   For More Information Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=175407912 The adoption of ORM solutions has been particularly affected by its high installation and maintenance costs. ORM software, when once installed, also requires to be regularly updated as per the user’s requirement and software enhancements, thereby presenting recurring expenditure. Additionally, the maintenance of high-end IT-enabled systems typically costs more than the software itself.  The annual maintenance cost is estimated to be 20-25% of the initial cost of the software licenses. Subsequently, it can be expected that the high costs incurred from the purchase, installation, maintenance, and upgrade of ORM software and solutions may negatively affect their overall adoption among end-users, thus restraining market growth to a certain extent.  Brazil, Russia, India, China, and South Africa (BRICS) are among the fastest-growing economies in the world. According to the World Economic Forum, these emerging economies will account for around one-third of the global healthcare expenditure by 2020. More than half of the world’s population resides in India and China, owing to which these countries are home to a large patient base. The increasing burden of cancer, improvements in healthcare infrastructure, a less-stringent regulatory environment, and growing medical tourism are encouraging players in the operating room management market to increase their presence in emerging countries. Owing to the expansion of the patient population base, the number of hospitals and surgical centers is also expected to increase in emerging countries in the coming years. Also, currently, governments in these countries are undertaking initiatives to expand and modernize their respective healthcare infrastructures.  The number of independent health care providers has been decreasing as most healthcare providers are turning to mergers, acquisitions, and partnerships and are functioning under a health system rather than operating independently. On a 15-year basis, the percentage of hospitals functioning under a health system has increased from approximately 50% to approximately 65%. Today, over 70% of hospitals are operating as part of a health system rather than independently.  Data management communication solutions accounted for the largest share of the operating room management market in 2019 owing to the benefits such as easy sharing of patient status in perioperative care phases, tracking of the schedule compliance, and sharing of the media and information related to cases within different operating rooms or external hospital departments.  The high growth of this segment can primarily be attributed to advantages such as scalable data storage, scalable computing power, machine-learning capabilities, and faster data transfer between organizations of cloud platforms.
Cleanroom Technology Market to Witness Impressive Growth
The increasing demand in developing economies and the growing focus on energy-efficient cleanrooms are expected to offer significant opportunities for market growth in the coming years. However, the high operational cost associated with the cleanrooms is expected to restrain market growth to a certain extent.  The global health crisis triggered by the COVID-19 pandemic has made it imperative that the pharmaceutical industry moves at a rapid pace alongside researchers, regulators, and contract research companies to develop a diagnosis, treatment, and vaccines. Cleanroom technologies and services play an important role in this scenario to ensure that quality, safety, and efficacy are being maintained.  In the current scenario, the healthcare industry is witnessing an unparalleled demand for diagnostic tests, personal protective equipment (PPE), medical ventilators, and other critical medical supplies. Facing the potentiality of a high risk of infection, healthcare professionals (HCPs) are also facing significant challenges in providing specific and effective care (often remotely).  In Hospital systems are becoming overwhelmed with the rapidly increasing number of COVID-19 patients, which is weighing heavily on the pharmaceutical industry. With the increasing demand for certified products, various quality certifications such as ISO checks and National Safety and Quality Health Standards (NSQHS) have been made mandatory for ensuring that the standards for manufacturing processes and products are being upheld. The quality certifications require products to be processed in a cleanroom environment to ensure minimum possible contamination.   Also, the price per square foot is not the same for ISO 6 and ISO 8 cleanrooms. This is because the amount of air supplied is different in both classes of cleanrooms. The air is 100 times cleaner in an ISO 6 cleanroom than in an ISO 8 cleanroom, thereby doubling the air conditioning capacity of the HVAC systems.   For More Information Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=263122482 Cleanrooms are mostly designed according to customer requirements based on product specifications and customer-specific design requirements. However, there are no specific guidelines for cleanroom designs for different application areas or product types. This leads to several challenges for cleanroom manufacturers, as they need to follow different designs every time.  The consumables segment accounted for the larger market share in 2019. The high and growing number of pharmaceutical, biotech, and medical device companies facilitating the use of disposable protective clothing has resulted in the increased adoption of the consumables in the cleanroom technologies market. Also, the large number of RD activities in the healthcare industry is resulting in a stable demand for cleanroom consumables among end-users.   The hardwall cleanrooms segment is expected to witness the highest growth during the forecast period. This is mainly due to the higher demand for hardwall cleanrooms, as they are more design-flexible than standard and softwall cleanrooms, quick and easy to install, freestanding for easy portability, and easy to expand or reconfigure.   This is due to its favorable government regulations, increasing healthcare expenditure, and the growing base of pharma companies in the country, all of which are driving adoption of cleanroom solutions in the Asia Pacific. 
7 Popular Types of Psychotherapy for a Variety of Mental Health Issues
Psychotherapy Overview: Individualized psychotherapy consultations frequently contain a discussion between experienced therapists and patients about specific encounters, thoughts, relationships, existing issues, and feelings to maintain a connection and provide understanding.  A few investigations showed individualized psychotherapy discussions end up being profitable in reducing psychological symptoms. For this reason, psychotherapy has developed into a diverse and well-known treatment for multiple psychiatric problems.  Couples, groups, and families use psychotherapy to determine psychological disorders. A mix of medication and therapy effectively handled several mental health problems.  There are a few kinds of talking therapy, however, they require working with experienced psychotherapists. These therapies assist you in determining the source of your problem. Talking therapy may incorporate one-to-one conversation, group conversation, online counsel, over a telephone conversation, in family, and with your partner.  Psychotherapy can help with complications, comprising adapting to day-by-day life; the effect of injury, clinical disease, or misfortune, similar to the passing of a friend or family member; and explicit mental problems, similar to anxiety and depression. In case you’re keen on attempting psychotherapy, ensure you do some exploration. There are upsides and downsides to each therapy, and what works for another person probably won’t work for you. Specialists isolated psychotherapy into two sorts: short-term and long-term. A short-term therapy session comprises a couple of sessions to manage minor problems.  Long-term therapy session involves months or a long time of sessions to handle chronic and complicated issues. The patient and specialist mutually plan the objectives of treatment and courses of action. Psychotherapy Types: There are various kinds of psychotherapy. The choice of treatment relied upon the patient’s mental ailment, adherence to the treatment, and inclination since psychotherapy turns out better for one individual, however, not for someone else. Psychotherapists join every one component and suggest such treatment that meets the prerequisites of the patients. Cognitive-Behavioral Therapy (CBT): CBT (Cognitive-behavioral therapy) is a type of psychotherapy that evaluates the connections between a person’s thoughts, conduct, feelings, and sentiments.  CBT can help you investigate and change how you consider your life, allowing you to break free from negative musings and undesirable practices.  Psychotherapists and their patients work together to establish productive solutions to overcome self-destructive practices and beliefs by analyzing such problematic thought patterns.  CBT, according to a few studies, can be utilized to treat a variety of psychiatric issues including Depression and Anxiety disorders Panic attacks and Phobias Bipolar Disorders Eating disorders (especially bulimia nervosa) Obsessive-compulsive disorder (OCD) Schizophrenia Post-traumatic stress disorder Dialectical Behavior Therapy (DBT): Dialectal behavior therapy (DBT) is another type of psychotherapy and is related to cognitive-behavioral treatment (CBT).  Its accentuation on revealing approval, grieved musings, tolerating undesirable considerations, sentiments, and feelings as opposed to managing them.  Experts initially developed DBT to treat persistently self-destructive patients with borderline personality disorder (BPD).  Over the long haul, therapists used DBT for treating different emotional well-being messes. Individuals who are treated with DBT have BPD as an essential finding.  Advisors use DBT to foster adopting procedures to manage the circumstance and assist them with learning the harmony among change and acknowledgment.  An article identified with the Mental Health Clinician shows DBT diminished clinical consideration and prescription up to 90%. Dialectal behavior therapy is being used to treat a variety of psychiatric disorders, including: Substance use disorder Eating related disorders Post-traumatic stress disorder (PTSD) Mood related disorders Eye Movement Desensitization And Reprocessing Therapy (EMDR): Eye Movement Desensitization And Reprocessing Therapy (EMDR) is a sort of psychotherapy explicitly used to treat PTSD.  According to a few studies, reliving traumatic situations with precise eye movements helps minimize the emotional suffering associated with them.  Although the effectiveness of EMDR is debatable, it tries to curtail the negative consequences of painful experiences and promote a positive transformation in the individual. Exposure therapy: Another type of psychotherapy that is related to cognitive-behavioral therapy is exposure therapy.  In this therapy, an individual works with an advisor to recognize anxiety triggers and learn procedures to try not to be restless when they encountered them.   After being exposed to these triggers, the individual will learn techniques to stay away from ritualistic habits or anxiety. Psychotherapists use exposure therapy to handle specific mental health conditions such as Obsessive-compulsive disorder (OCD) Phobias PTSD Interpersonal therapy: Interpersonal therapy is a sort of psychotherapy that spotlights the connections an individual has with others, determined to work on the individual’s relational abilities.  In this type of psychotherapy, the specialist assists individuals by assessing their social communications and perceiving negative exemplars, similar to social confinement or animosity, and at last assists them with learning procedures for comprehension and cooperating decidedly with others Mentalization-based therapy: According to randomized clinical preliminaries, Mentalization-based treatment (MBT) can carry long haul improvement to individuals with borderline personality disorder (BPD).  MBT is a sort of psychotherapy that draws in and practices the significant expertise called mentalizing.  Its essential point is to give an individual with BPD a self-appreciation and assist them with interfacing with others. Psychodynamic Psychotherapy: Psychodynamic treatment endeavors to perceive negative exemplars of conduct and feeling that are established in past encounters and resolve them. This sort of psychotherapy frequently employs indefinite questioning so that individuals have the chance to talk about whatever is in their brains. Psychodynamic therapy is effective in the treatment of a variety of psychiatric issues, including: Major depressive disorder/ depression Anxiety disorders In Borderline personality disorder There are distinctive psychotherapy accessible for managing certain mental conditions. Be careful while picking a particular kind, it very well may be conceivable what works for different patients probably won’t work for you. If you are unsure about which treatment will satisfy your necessities, talk with your therapist or medical care guide.
Real World Evidence Are Used To Monitor The Post Market Safety and Adverse Events of Drugs
The emergence of this pandemic has posed severe financial constraints on pharma-biopharma companies in several countries. In this regard, RWE solutions have proven to be very helpful, as they allow industrial and academic researchers to monitor patients using digitally connected platforms while helping to organize and evaluate clinical data for regulatory submissions. The uncertainty brought on by the COVID-19 pandemic has dramatically shifted how and when patients decide to seek medical care. In addition, shifts in healthcare coverage and provision during the pandemic have changed the discovery and reporting of certain outcomes in data and the treated population. This means that disease trends may lead to incorrect interpretations when RWD and RWE are not framed in the context of the pandemic and long-term COVID-19 disease, therapy, and lifestyle changes.   RWE is set to become the most influential emerging technology to help in the fight against the COVID-19 outbreak, according to the latest poll on GlobalData’s Pharmaceutical Technology website. In this poll, which was completed by 935 of its readers in April 2021, more than one-third of the respondents indicated that RWE would have the greatest impact on the management of COVID-19.  Even though emerging technologies, such as telemedicine, have existed for decades, most of healthcare systems rely heavily on in-person interactions between patients and clinicians. Nevertheless, the current requirement for social distancing measures is swiftly pushing the primary care provision toward remote care. Telemedicine and virtual care may also prompt a greater adoption of technologies such as wearables and digital therapeutics, thus accelerating digitalization in the healthcare space and boosting the importance of RWE and AI.  Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=76173991 The utilization of RWE in infectious disease control is not a new concept. During the Ebola outbreak in 2014, forecasters successfully used Global Epidemic and Mobility (GLEaM) simulations that combined real-world data on populations and their mobility with rigorous stochastic models of disease transmission to predict the global spread of the disease.  In countries with strict data privacy laws, the implications of contact-tracing apps on individual privacy are considered a major associated concern. While cryptographers are currently working on improving tracing apps to address the issue, tracking apps can only be effective when they are used by a significant proportion of the population. Therefore, it is critical that the functionality and safety of these applications are considered acceptable by the majority of the population.  Through the analysis of the data generated from various networks, healthcare organizations can benefit from sensible information, resulting in real-time disease monitoring and control. However, as the use of technology as a means to produce more and more data to drive insights and foresight increases, the ability to automate and analyze that data becomes a necessity. Accelerated digitalization in the healthcare space has revealed gaps in infrastructure, workforce, and digital education that ultimately need to be bridged.   Real World Evidence Solutions Market Dynamics Without intelligent analytics, RWE alone will not be able to produce meaningful and actionable results. Previously, the healthcare industry did not have the ability to gather RWE at the speed and scale needed to address urgent public health crises. However, this scenario has changed due to the pandemic. Advances in analytics and access to broad and diverse real-world data sets have made it possible to rapidly analyze data as it is captured to better understand how pandemics like COVID-19 are unfolding.  The pre-approved use of RWE in efficacy decisions is being carried out currently, and there is potential for it to be used more broadly, such as in oncology, rare diseases, and pediatric conditions when randomized controlled clinical trials are impossible or unethical to conduct. In parallel, legislators are recognizing the value of RWE. In the US, the 21st Century Cures Act, passed in December 2016, has established public-private partnerships to collect data and improve the understanding of diseases. 
How Impacted COVID-19 on Neural Implant in Healthcare Industry ?
Impact of COVID-19 on Neural Implant in Healthcare Industry The COVID-19 pandemic has stood as a complex challenge in front of several healthcare companies and proved to be a global health threat. The first case of the COVID-19 pandemic was found in Wuhan, China. This virus had emerged in December 2019 and has been proven as a global pandemic by WHO in March 2020. Patients with other respiratory disorders such as Chronic Bronchitis, Lung Cancer, and Pneumonia are more susceptible to COVID-19. This pandemic has created a health crisis, and it has adversely affected our economies, healthcare and pharmaceutical sectors, and their core. As the number of COVID-19 (coronavirus) cases continues to rise in the U.S., Russia, France, and Brazil, life-threatening and rare brain diseases are being linked to the infection. This has brought companies in the brain implants market into the picture since their assistance is crucial in the already stressed healthcare facilities. Neural implant technology is highly innovative and is expected to influence the existing treatment modalities of neuropathic disorders and chronic neuropathic pain. The introduction of neural implants has been a significant breakthrough because of their high potential in minimizing the occurrence of adverse events associated with Parkinson's disease, chronic pain, epilepsy, and other neural disorders. Therefore, the adoption of neural implants is likely to increase at a phenomenal rate in the coming years. Healthcare professionals were often redeployed to emergency patterns of working, sometimes outside of their usual scope of practice. Thus, the urgent and routine care for millions of patients with non-COVID illnesses has been interrupted. IMPACT ON DEMAND The COVID-19 pandemic is expected to have a significant impact on the growth of the brain implants market globally, due to the suspension and postponement of most of the elective surgeries and treatment during the pandemic, to reserve the hospital infrastructure and staff in treating COVID-19, infected patients. According to the research article published in medRXiV, 2021, the prevalence of SARS-COV2 viral infection in patients with Parkinson's disease was found to be 11.28% and COVID-19 prevalence in Parkinson's disease patients with deep brain stimulation was found to be 18.18%. Additionally, as per the research study published in Frontiers in Neurology, 2020, the motor and psychiatric symptoms in Parkinson's Disease patients and dystonic patients treated with Deep Brain Stimulation was observed to have worsened during the lockdown restriction measure, and further, this had led to increased stress in the management of neurological disorders. Additionally, according to the research article published in JAMA Neurology, 2020, among 214 patients with COVID-19, neurologic symptoms were seen in 36.4% of patients. Thus, patients suffering from COVID-19 are prone to a high risk of developing neurological disorders during their hospital stays. Thus, owing to the strict lockdown restrictions and measures taken to contain the viral transmission, the chronic stress and burden of neurological disorders had increased, which required the urgent opening of the neurological outpatient services, and thus, the brain implants market is expected to have impacted significantly during the pandemic. The increase in the number of cases of neurological disorders, such as Alzheimer’s, epilepsy, Parkinson’s, depression, and essential tremors, is anticipated to propel the demand for brain implants. Brain implants are likely to reduce the need for drugs that relieve chronic pain and improve body movement in patients suffering from Parkinson’s or any other neurological disease. The growing geriatric population is also prone to order surgical disorders and thus, aging is the major factor that is driving the market growth for brain implants. According to the United Nations, World Population Ageing 2019 report, more than 703 million people were aged 65 years and above in 2019 and are expected to reaching 1.5 billion by 2050. IMPACT ON SUPPLY Due to the pertinacious COVID-19 lockdown in various countries, sanctions have been forced by administrations of different nations. These limitations and boundaries across the nation’s borders prompted a diminishing stockpile because of restricted materials and labor force and the halting of the assembly line. It has been found that certain individuals in their late ’50s are at risk of developing acute necrotizing encephalitis, which is a rare complication of influenza and other viral infections. This has fueled the growth of brain implants to maintain steady supply chains to meet the demand. Acute necrotizing encephalitis has the potential to cause seizures and confusion, and in serious cases, can lead to coma. This has triggered the need for developing strong research databases to address complications of COVID-19. STRATEGIC DECISIONS BY MANUFACTURERS The presence of key players in the region and the increasing number of product approvals is expected to drive the studied market growth. For instance, · In June 2020, US FDA approved Medtronic plc's Percept deep brain stimulation (DBS) for the treatment of Parkinson’s symptoms. The major market players are focusing on technological advancement to acquire maximum market share. For instance, · In January 2021, Abbott Laboratories launched its NeuroSphere my Path, a Digital Health app that was developed to track and report on pain relief in chronic pain patients and general well-being associated with spinal cord stimulation (SCS) or dorsal root ganglion (DRG) therapy. · In March 2021, Abbott Laboratories announced the launch of NeuroSphere Virtual Clinic, which is a remote neuromodulation patient-care technology in the United States. · In March 2020, LivaNova plc received CE Mark approval for its Vagus Nerve Stimulation Therapy (VNS Therapy) System, "Symmetry", for Difficult-to-Treat Depression (DTD). · BrainCom— a collaborative research project that aims to develop a new generation of neuroprosthetic devices is being funded by the European Union under the FET Proactive funding scheme to advance speech neural prostheses. Companies in the brain implants market are increasing the availability of solutions for people suffering from motor diseases and neurological conditions. Such implants are bolstering market growth, as they have the potential to eliminate the need for open brain surgeries. · Dell Technologies— a U.S. multinational computer technology company is gaining strong business grounds in transformative technologies for brain implants by collaborating with think tanks and neuroscientists. In June 2018, Medtronic plc announced that the US Food and Drug Administration approved Deep Brain Stimulation (DBS) Clinician Programmer and Activa(TM) Programming Application. The Activa Programming Application has been uniquely designed with the input of over a hundred clinicians from around the world and is managed on the Samsung Galaxy Tab S2 tablet interface. In February 2016, ALEVA NEUROTHERAPEUTICS SA announced a collaboration with Greatbatch for a next-generation device for Deep Brain Stimulation (DBS). Under the terms of the development agreement, Greatbatch’s design and development team QiG Group, which is expected to be spun off as Nuvectra Corporation, will provide Aleva with access to its unique implantable neurostimulation platform. Companies in the brain implants market are increasing the availability of less invasive solutions since the brain is one of the most delicate and sensitive body organs. They are decoding the symphony of neural activity to stimulate brain function. CONCLUSION Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Brain Implants market in 2020.
What COVID-19 Impacted on Blood Lancet in Healthcare Industry ?
Impact of COVID-19 on Blood Lancet in Healthcare Industry The first case of the COVID-19 pandemic was found in Wuhan, China. This pandemic has influenced the whole planet with its significant impacts on the economy and businesses worldwide. The COVID-19 spread worldwide in unprecedented ways due to its high infectious and contagious nature. As a result, the most outstanding medical challenge in the 21st century is yet to face physicians worldwide. Though the emergence of the virus can be tracked back to Asia, many European countries and the U.S. have been struck massively by the pandemic. The virus has spread across all regions ranging from North America, Europe, Asia-Pacific, Middle East and Africa up to South America. The COVID- 19 has been declared a pandemic by World Health Organization (WHO) due to its increased spread globally. After the pandemic declaration, various countries announced the complete lockdown such as the Russia, Europe and Asian countries, to decrease its spread. Regardless of the pandemic of COVID-19, the demand for blood lancets has increased in healthcare applications. Blood lancets are scalpel-type medical instruments with a double-edged blade used for various diseases for blood diagnosis procedures in hospitals, clinics and the home healthcare arena. According to the situation report of 11th May 2021 by World Health Organization (WHO) stated 157 million cases of coronavirus patients had been reported globally and 3.3 million patients are dead due to the coronavirus. America is leading in cumulative cases with a record of 64 million and 1.5 million death rates. At the same time, nearly 1.45 billion doses of COVID-19 vaccines have been administered globally. The outbreak of COVID-19 has a significant impact on the healthcare and supply chain of various medical devices and kits, including blood lancets. IMPACT ON DEMAND The COVID-19 pandemic has lifted the blood lancet market from its niche pedestal to the mainstream sector. However, even before the pandemic, blood lancets' demand was highly interested in rising chronic diseases such as diabetes, hyperlipidemia and more. For instance, · As per World Health Organization's (WHO) report released on 13th April 2021, the diabetes cases raised from 108 million to 422 million from 1980 to 2014, specifically higher in middle and low-income countries. · In 2019, 1.5 million death rates were directly estimated for diabetes. The rising research and technologies in the medical sector have made various types of blood lancets invade specific applications. These lancets are disposable, which surges its application for pain-free and safe blood diagnosis. This also minimizes the risk of blood transfusion and infection transmissions. The coronavirus pandemic has further increased the demand for blood lancets since COVID-19 can also be diagnosed using a blood test. For instance, · As per the 14th September 2020 published report of the U.K. Government, their coronavirus antibody test kits are delivered home for simple blood sample tests. The limited amount of blood can be drawn using finger-prick disposable blood lancets and provided to labs for 3-7 days results. In the current scenario, coronavirus's rising transmission rate has made homecare and self-diagnosis kits and procedures highly prevailing in the market. Due to its disposable nature, painless and easy usability blood lancets are highly preferred by healthcare professionals in chronic infection diagnosis. Several companies operating in other domains are eager to enter. Some have already entered the landscape of the blood lancet market to increase their revenue by meeting the emergent need of diagnosis kits and blood tests for the virus infection. The demand is further rising in local clinics and small laboratories for blood sugar and lipid testing. Furthermore, the coronavirus lockdown and lack of hospital admissions for other chronic diseases as diabetes have boosted self-monitoring diagnostic procedures among patients. Since blood lancets an ideal device for self-diagnosis, this has increased the market demand to a greater extend. The rising geriatric population and obese individuals, because of unsanitary food habits and lack of physical exercise, have increased chronic illness cases as diabetes on hype. The life-threatening diseases are compelled to be maintained and treated often, which raises the diagnosis requirements globally. Therefore, the affirmative factors boost the demand for blood lancets among patients. PRICE IMPACT The COVID-19 had a devastating impact on the global economy. The several establishments have to remain shut while others scale down the operations or put on hold expansion plans as they tried to survive the unprecedented crisis. However, the demand for blood lancets has been rising because of the increasing prevalence of diabetes patients and their routine self-care diagnostic management. Despite lockdowns and supply disruption crises during this pandemic, the companies manage online sales and delivery of blood lancets without the mandatory requirement of prescriptions. They are also maintaining fair prices owing to the high demand for blood lancets in the market. For instance, · Ever Ready First aid twist cap blood lancets of 500 counts per package costs USD 10.00, which is delivered home with high safety precautions. · Apollo Pharmacy provides home delivery for blood lancets conveniently considering the product under the counter category. The COVID-19 impact has not affected the price of blood lancets at a high level because of advanced online sales and innovative delivery options available with the utmost safety concerns. IMPACT ON SUPPLY CHAIN The COVID-19 has created a significant impact on the supply chain of the blood lancet market. The sudden attack of COVID-19 and its subsequent implications for restrictions on trade and movement of goods has resulted in a shutdown of vast countries globally, resulting in disrupted supply chains due to limited materials and workforce and slow down or stopping of manufacturing. Moreover, several manufacturing companies are retooling priority manufacturing to produce other essential medical supplies and equipment such as ventilators. But since the blood lancets are in high demand by various healthcare sectors, the supply chain is again gaining speed due to an increase in order from the consumers. The government allows the moments of transport vehicles to import and export the raw materials to produce lancets. Additionally, the manufacturers are also taking crucial steps to ensure the availability of raw materials by and also they have to look into the quality of products. Therefore, manufacturers need to take necessary steps about production processes, shifting to other facilities if required, changes in quality assurance, costs and procedures related to screening workforce and offering of care if needed, changes in working hours and others to maintain their supply chain. To minimize supply chain crises, the government has been firmly monitoring the supply chain to assume that the COVID-19 outbreak may adversely impact the supply chain of a medical product, including shortages of blood lancets for various healthcare sectors countries globally or potential disruptions in supply chains. To manage such a crucial situation, many organizations are looking forward to improving and diversifying the supply chain model in all aspects. For instance, · Roche Diabetes Care has taken initiatives for uninterrupted Accu-Chek diabetes test kits and lancet products supply during this health crisis of COVID-19 lockdowns. They are supplying homes with their diabetes self-management lancets and lancing devices with online booking and free delivery without the requirement of prescriptions. · They have also reported that the COVID-19 pandemic has not impacted their supply because of the robust manufacturing facility and evolving solutions. The resulting COVID-19 pandemic has shown the various ways for supply chain management, which may be effective by innovative solutions initiated by the market players. CONCLUSION The impact of the novel COVID-19 virus is expected to leave a long-lasting effect on each healthcare sector. The outbreak of COVID-19 prompted citizens to deal with confusion regarding the virus and its management. The virus poses a risk to human life and has caused economic distress and severe emotional strain. In addition, it produced a ripple effect that gave rise to a new collection of requirements and needs that were not much needed earlier and the essential one being the blood lancets which is highly required in hospitals, clinics, labs and home healthcare setups. It is estimated that the COVID-19 pandemic outbreak was having a positive impact on the growth of the blood lancet market owing to the requirement of self-diagnosis and management by numerous diabetic patients worldwide. Moreover, many international governments, including the U.S, Europe and Asia's healthcare organizations, have supported the supply of blood lancets and other diagnostic kits in the medical and home healthcare arena due to high priority and essential requirements for a crucial health crisis period. Many government bodies and significant market players are closely associated with chronic patients and healthcare professionals for better home care and self-diagnosis, considering the contagious nature of the virus and improvement of future economics with disposable blood lancets.
COVID-19 Impact on Primary Pulmonary Hypertension (PPH) Treatment in Healthcare Industry | Data Bridge Market Research
COVID-19 Impact on Primary Pulmonary Hypertension (PPH) Treatment in Healthcare Industry Coronavirus (COVID-19) is an infectious disease caused by coronavirus 2 (SARS-CoV-2) and, thus, being a novel cause of sepsis. COVID-19 is a type of ARDS (acute respiratory distress syndrome) that originated in Wuhan, China. Due to its highly infectious nature, this disease is still spreading throughout the world. Although vaccines are now available in the market, due to various challenge (large scale manufacturing of novel vaccine, national vaccination protocol, availability of the vaccine, new variants of COVID-19, lesser quarantine strictness), it has not been able to slow down or stop the virus from spreading globally. In the treatment of COVID-19 patients with ARDS, Prostacyclin (a vasodilator), primarily known for treating pulmonary arterial hypertension (PAH), has shown promising results in many studies. Price Impact COVID-19 pandemic has a huge impact on every market globally. The cases of PAH are rising in the range of 100,000 to 200,000 per year. However, in the past few years, PAH has been increasing due to risk factors such as alcohol/tobacco consumption, HIV, sedentary lifestyle, smoking, and other idiopathic conditions. Increasing yearly demands and using Prostacyclin in the treatment of ARDS (COVID-19) patients has affected all major manufacturers of the drug. For instance: · Remodulin (Treprostinil) a drug sold by United Therapeutics Corporation. A standard single dose of 20 milliliters 1 mg/ml Remodulin cost has gone from USD 45 (2017) to USD 69.94 (2021) Prostacyclin manufacturing leaders (United Therapeutics Corporation, Janssen, GlaxoSmithKline, and Sandoz) worldwide face export restrictions that directly affect the product's market cost. An additional increase in demands due to COVID-19 treatment is anticipated to impact significantly the forecast period. Impact on Demand There is no specific and approved treatment to treat the Coronavirus disease (COVID-19), apart from prevention by social distancing and, now, using vaccination. However, inhalation of prostacyclin vasodilator has been shown to work synergistically with COVID-19 medication to recover ARDS patients on ventilators. Coupled with the uncapped spread of the virus. For instance: · Hamad Medical Corporation - Inhaled Iloprost (Phase II) for Suspected COVID-19 Respiratory Failure (ILOCOVID) Moreover, the geriatric population is more prone to PAH and associated diseases owing to reduced immune function. According to the National Council on Aging (NCOA), about 80% of the population aged 65 and above have at least one chronic condition: high cholesterol, diabetes, heart or kidney disease, or chronic obstructive pulmonary disease. Hence the market for global PPH treatment is speculated to boom in the forecasted period. Impact on Supply Chain COVID-19 restrictions and lockdown have affected the supply chain of all manufacturing firms globally. Prostacyclin (Europe and Asia-Pacific) primary manufacturer was under complete lockdown, causing manufacturers to shut down (temporarily) supply chains. For instance: · By the end of July 2020, nearly 90 countries had introduced export restrictions due to the COVID-19 pandemic, according to the WTO. Since January 2020, countries have taken more than 197 actions banning or limiting the export of certain products, according to Global Trade Alert · Overall, the U.S. exports to the world were down USD 8.47 billion when comparing the first two months of 2021 to the same period of 2019 To tackle these unique challenges, manufacturers are looking for innovative ideas and complete re-thinking of supply chains. Remote work has been another unique restraint put forth by mandatory lockdown, which requires a completely novel approach towards supply chain processes. Strategic Decisions for Manufacturers Sudden demand surge and lockdown caused temporary roadblocks. The shutdown of international transport and supply chains also requires immediate remedies. Manufacturers, to combat challenges presented by the COVID-19 pandemic, devised various ideas. New product launches, remote working environment, recommencing supply chain manufacturing with social distancing restrictions are some strategic decisions made by manufacturers For instance: · Beth Rhodes, Vice President, Global Supply Chain & Alliance Management at United Therapeutics said, “We are excited to bring to market the first subcutaneous pump designed specifically for PAH patients. Remunity is a small, discreet pump that delivers Remodulin in prefilled cassettes that are delivered directly to patients, offering significant improvements over current subcutaneous pumps” – CONCLUSION It is predicted that COVID-19 has a major impact on the primary pulmonary hypertension (PPH) treatment market. Increased PPH drugs (Remodulin, Flolan, Veletri, Ventavis) and strict trade policies globally have pushed manufacturers into considering new and compatible market strategies. However, increase the prevalence of pulmonary hypertension, robust drug pipeline, and changing lifestyle, drives the global primary pulmonary hypertension (PPH) treatment market. Moreover, technological advancement in treatment & diagnosis and growing genetic mutation-related disorders also boost up market growth. But adverse effects related to the treatment, unknown causes behind the disease, and difficulty in diagnosis of primary pulmonary hypertension (PPH) treatment may hamper the global Primary pulmonary hypertension (PPH) treatment market.
Significant Impact of COVID-19 on Bioresorbable Scaffolds in Healthcare Industry
COVID-19 Impact on Bioresorbable Scaffolds in Healthcare Industry Coronavirus disease 2019 (COVID-19), also known as SARS-CoV-2 or 2019-nCoV, is a human infectious disease caused by the coronavirus that causes severe acute respiratory syndrome. COVID-19 was declared a pandemic by the world health organization due to the rapid rise in human infection rates. This pandemic has influenced the whole planet with its major impacts on the economy and businesses across the globe. The virus has spread across all regions ranging from North America, Europe, Asia-Pacific, Middle East, and Africa up to South America. After the pandemic declaration, various countries such as Russia, Europe, and Asia announced the complete lockdown to decrease its spread. During this pandemic of COVID-19 the rising prevalence of cardiovascular diseases and accompanied surgery adoptions is accelerating the market growth. Amid this pandemic the demand for bioresorbable scaffolds is increasing as they provide complete resorption and temporal mechanical support for patients. According, to the situation report of 20 July 2021, by WHO, 190 million cases of coronavirus patients have been reported globally, and 4.08 million patients are dead due to the coronavirus. America is leading in cumulative cases with a record of 74 million and 1.9 million death rates. More than 4.21 billion doses of Covid-19 vaccines have been administered in around 180 countries. The outbreak of COVID-19 is having a huge impact on the healthcare and supply chain of various medical products, including Bioresorbable scaffolds. Bioresorbable scaffolds are widely used as potential solution for coronary artery diseases. These scaffolds prevent the adverse reactions caused by permanent metallic devices during percutaneous coronary intervention, which is safe, effective, and timely preferred treatment for coronary artery diseases. Usually, permanent metallic devices prevent the natural process of vessel restoration and remodeling, which makes future revascularization more complicated. Hence, bioresorbable scaffolds are preferred to prevent these complications since they can provide temporary support and then degrade for natural restoration to take over in vessels. Price Impact The COVID 19 had a devastating impact on the global economy. The several establishments had to remain shut while others scaled down the operations or put hold on expansion plans as they tried to survive the unprecedented crisis. However, the rising cardiovascular cases increased the demand for vascular restoration surgeries. In spite of lockdowns and supply disruption crisis during this pandemic, the companies managed and are still managing online sales for many medical scaffolds and their products. They are also maintaining fair prices due to the high demand of these products in the market, but due to the supply chain disruption, the prices have raised slightly. For instance, · As per a survey done in five U.S Hospitals, the price of scaffold Bioresorbable stents was estimated to be 1, 250 USD per stent. And Abbott sells Bioresorbable Vascular Scaffolds BVS for USD 1,743 and Everolimus-Eluting Bioresorbable Scaffolds EES for USD 1,638 The COVID-19 impact has not affected the price of scaffolds and based products at a high level because of advanced online sales and innovative delivery options available with utmost safety concerns to major coronary surgeries conducted in hospitals. Impact on Demand The COVID-19 pandemic has impacted the bioresorbable scaffolds market from its niche pedestal to the mainstream sector. Even before the pandemic, the bioresorbable scaffolds were in high demand due to rising chronic coronary artery diseases and advanced methods for treatments of these diseases like vascular restorations globally. For instance, · As per the American College of Cardiology in 2018, the use of stent scaffolds in cardio surgeries started back in mid-1980s. But due to many adverse reactions of metallic scaffolds, which resist the natural vascularization process in arteries, researchers showed wide interest in bioresorbable scaffolds The rising transmission rate of coronavirus in the recent scenario has made high hospital admissions for various chronic diseases and respective demand for surgical scaffolds. The most widely used bioresorbable scaffold is ‘Absorb BVS’, made of PLLA scaffold coated with Everolimus-Eluting PDLLA. This is 150 micron size which can reabsorb for 4 years altogether. Coronary artery disease is major heart disease that affects both men and women irrespective of age globally. For instance, · According to the Center for Disease Control CDC; coronary heart disease has been estimated to be around 18.2 million in adults aged 20 and above. In 2017, the mortality rate was 365,914 due to coronary artery diseases. About 2 out of 10 individuals are killed due to the disorder in adults who are less than 65 years of age. This increases the demand for surgeries and vascular restoration for the timely treatment of most coronary disease conditions. Several companies operating in other domains are eager to enter, and some have already entered the landscape of bioresorbable scaffold market to increase their revenue by meeting the emergent need of various hospitals for coronary artery surgeries. The demand is further rising in local clinics and small laboratories due to high awareness of the disease and their advancements in surgical procedures. Impact on Supply Chain The COVID-19 has created a great impact on the supply chain of bioresorbable scaffolds. The sudden attack of COVID-19 and its subsequent impact on restrictions on trade and movement of goods has resulted in a shutdown of vast countries globally, resulting in disrupted supply chains due to limited raw materials and workforce, and slow down or stopping of manufacturing. Moreover, several manufacturing companies are retooling priority manufacturing to produce other essential medical supplies and equipment such as ventilators. But considering the need of these scaffolds in coronary heart diseases surgery and an increase in order from the consumers, the government allows the movements of transport vehicles to import and export the medical and surgical scaffold or implants products which is highly required by hospitals and other healthcare sectors. Additionally, the manufacturers are also taking crucial steps to ensure the availability of raw materials and look into the quality of products. Manufacturers need to take necessary steps about production processes, shifting to other facilities if required, changes in quality assurance, costs and procedures related to screening of workforce and offering care if needed, changes in working hours, and others in order to maintain their supply chain. To minimize supply chain crises, the government has been firmly monitoring the supply chain to assume that the COVID-19 outbreak may adversely impact the supply chain of medical products, including shortages of bioresorbable scaffolds for various surgical purposes to coronary healthcare sectors in countries globally or potential disruptions in supply chains. To manage such a crucial situation, many organizations are looking forward to improving and diversifying the supply chain model in all aspects. The resulting COVID-19 pandemic has shown the various ways for supply chain management, which may be effective by innovative solutions initiated by market players. STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS The key players engaged in the global bioresorbable scaffolds market are making improvements to keep the speed during COVID-19. They are cautiously taking every single step so the development can be expanded on a consistent schedule for the market. Organizations working in the bioresorbable scaffolds market embrace a few systems, including joint effort, arrangements, association, and market development to improve their business. For instance, · On September 3, 2020, Abbott, the primary key player in the bioresorbable scaffolds market, announced that they had initiated a LIFE-BTK clinical trial for evaluating the effectiveness of Esprit BTK Everolimus Eluting Resorbable Scaffold, which was used for people battling with late stages of peripheral artery disease (PAD). Even during the pandemic, the company is making many initiatives to resume their products manufacturing and trial over the market to strengthen their position. Conclusion The impact of the novel COVID-19 virus is expected to leave a long-lasting impact on each healthcare sector. The virus poses a risk to human life and has caused economic distress and severe emotional strain. It produced a ripple effect that gave rise to a new collection of requirements and needs that were not much needed earlier. The most essential one being the bioresorbable scaffolds and medicinal products, which are highly needed in hospitals, clinics, laboratories due to rising chronic cardiovascular and coronary artery diseases and surgical emergence globally. It is estimated that the COVID-19 pandemic has a negative impact on the market's growth due to the surgery cases of coronary diseases being halted unless emergence. The current priority in most hospitals is given for COVID-19 treatments as the surge of COVID-19 cases keeps increasing each day. Moreover, many International governments, including U.S, Europe and Asia’s healthcare organizations, have supported the supply of these scaffold products due to high priority in this crucial health crisis period. Many government bodies and significant market players are closely associated with patients and pharma industries for safe packaging of products considering contagious nature of the virus and improvement of future economics.